Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

Executive Summary

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.


Related Content

DTC Ad Price Disclosure Provision Stripped From US Funding Bill
Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means
Congressional Action On Drug Pricing Blueprint Likely To Be Modest
Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves
Drug Importation Blocked But Not Forgotten As User Fee Bill Clears Senate Cmte
EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts